Possibilities of diagnosing latent tuberculosis infection using recombinant tuberculosis allergen in patients with rheumatological diseases

A. V. Mordyk; Мордык А. В.; M. A. Romanova; Романова М. А.; A. I. Nurgaleeva; Нургалеева А. И.; Natalya V. Bagisheva; Багишева Наталья Викторовна; A. A. Shapran; Шапран А. А.; M. V. Moiseeva; Моисеева М. В.; L. E. Shcherbakova; Щербакова Л. Э.; A. I. Mazur; Мазур А. И.; P. S. Shatova; Шатова П. С.; D. I. Mordyk; Мордык Д. И.; D. A. Kudlay; Кудлай Д. А.

doi:10.18565/pharmateca.2024.4.115-120

Possibilities of diagnosing latent tuberculosis infection using recombinant tuberculosis allergen in patients with rheumatological diseases

作者: Mordyk A.V.¹^,2, Romanova M.A.¹, Nurgaleeva A.I.¹, Bagisheva N.V.¹, Shapran A.A.³, Moiseeva M.V.¹, Shcherbakova L.E.¹, Mazur A.I.¹, Shatova P.S.¹, Mordyk D.I.⁴, Kudlay D.A.⁵^,6^,7
隶属关系:
1. Omsk State Medical University
2. National Medical Research Center for Phthisiopulmonology and Infectious Diseases
3. Omsk Central District Hospital
4. Main Bureau of Medical and Social Assessment for the Omsk Region, Branch No. 17
5. I.M. Sechenov First Moscow State Medical University (Sechenov University)
6. State Scientific Center “Institute of Immunology of the Federal Medical and Biological Agency”
7. Lomonosov Moscow State University
期: 卷 31, 编号 4 (2024)
页面: 115-120
栏目: Pulmonology/ENT/ARVI
URL: https://journals.eco-vector.com/2073-4034/article/view/641664
DOI: https://doi.org/10.18565/pharmateca.2024.4.115-120
ID: 641664

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅或者付费存取

详细
全文:
作者简介
参考
补充文件
统计

详细

Background. Against the background of the therapeutic effectiveness of genetically engineered biological preparations (GEBPs) that affect immune cells, patients with rheumatological diseases increase the risk of developing tuberculosis infection.

Objective. Evaluation of the role of immunodiagnostics and the results of a test with the recombinant tuberculosis allergen (RTA) in the detection of latent tuberculosis infection in rheumatological patients undergoing biological therapy.

Methods. 26 outpatient records of patients in the Omsk district of the Omsk region for 2020–2023, receiving biological therapy for the treatment of rheumatological diseases were analyzed, and the prevalence of tuberculosis infection among these patients was assessed.

Results. Of the 26 patients, latent tuberculosis infection was diagnosed in 5 (19.23%) patients based on the examination. In 4 out of 5 patients, the RTA test was positive: a moderate reaction in 2 – 6 and 9 mm, a pronounced reaction in 1 – 14 mm, a hyperergic reaction in 1 patient – 15 mm, 1 patient – doubtful. By decision of the Central Medical Commission of the Clinical Tuberculosis Dispensary, patients were given a preventive course of anti-tuberculosis therapy. During the follow-up period, the study group managed to avoid the development of active tuberculosis infection and continue treatment of the underlying disease using genetic engineering biological therapy.

关键词

latent tuberculosis infection, genetic engineering biological therapy,, tumor necrosis factor α, rheumatological diseases

全文:

作者简介

A. Mordyk

Omsk State Medical University; National Medical Research Center for Phthisiopulmonology and Infectious Diseases

Email: ppi100@mail.ru
ORCID iD: 0000-0001-6196-7256
俄罗斯联邦, Omsk; Moscow

M. Romanova

Omsk State Medical University

Email: ppi100@mail.ru
ORCID iD: 0000-0002-1775-607X
俄罗斯联邦, Omsk

A. Nurgaleeva

Omsk State Medical University

Email: ppi100@mail.ru
俄罗斯联邦, Omsk

Natalya Bagisheva

Omsk State Medical University

编辑信件的主要联系方式.
Email: ppi100@mail.ru
ORCID iD: 0000-0003-3668-1023

Cand. Sci. (Med.), Associate Professor, Department of Outpatient Therapy and Internal Medicine

俄罗斯联邦, Omsk

参考

Ассоциация ревматологов России. URL: https://rheumatolog.ru/patient/about_rz/zabolevaniya/o_rz/ (дата обращения: 05.12.2023). [Association of Rheumatologists of Russia. URL: https://rheumatolog.ru/patient/about_rz/zabolevaniya/o_rz/ (date of access: 05.12.2023). (In Russ.)].
ВОЗ – Глобальный доклад о туберкулезе за 2020 год. URL: https://www.who.int/publications/i/item/9789240013131. (дата обращения:10.12.2023). [WHO – Global report on tuberculosis for 2020. URL: https://www.who.int/publications/i/item/9789240013131. (date of access: 10.12.2023). (In Russ.)].
Галушко Е.А., Насонов Е.Л. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018;1. [Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Almanac of Clinical Medicine. 2018;1. (In Russ.)].
Клинические рекомендации. Ревматоидный артрит. 24.08.2021. МЗ РФ. [Clinical guidelines. Rheumatoid arthritis. 08/24/2021. Ministry of Health of the Russian Federation. (In Russ.)].
Белов Б.С., Тарасова Г.М., Буханова Д.В. Коморбидные инфекции у больных ревматоидным артритом: status praesens. Современная ревматология. 2019;13(3):102–8. Belov B.S., Tarasova G.M., Bukhanova D.V. Comorbid infections in patients with rheumatoid arthritis: status praesens. Sovremennay revmatologiay. 2019;13(3):102–8. (In Russ.)].
Скрининг и мониторинг туберкулезной инфекции у больных, получающих иммуносупрессивные генно-инженерные биологические препараты. Методические рекомендации. М., 2018. [Screening and monitoring of tuberculosis infection in patients receiving immunosuppressive genetically engineered biological drugs. Methodical recommendations. Moscow, 2018. (In Russ.)].
Anton C., Machado F.D., Ramirez J.M., et al. Latent tuberculosis infection in patients with rheumatic diseases. J Bras Pneumol. 2019;45(2):e20190023. doi: 10.1590/1806-3713/e20190023.
Chiu Y.M., Chen D.Y. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2020;16(2):207–28. doi: 10.1080/1744666X.2019.1705785.
Rath E., Bonelli M., Duftner C. Consensus Statement der Österreichischen Gesellschaften fur Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder «targeted synthetic» DMARDs («disease modifying antirheumatic drugs»). J Rheumatol. 2023;82:163–74.
Slogotskaya L., Litvinov V., Kochetkov Ya., et al. New skin test with recombinant protein CFP10-ESAT6 in patients (children and adults) with tuberculosis, non-tuberculosis disease and latent TB infection. Eur Respir J. 2012;40(56):416.
Slogotskaya L.V., Bogorodskaya Е., Ivanova D., et al. Sensitivity and specificity of new skin test with recombinant protein CFP10-ESAT6 in patients with tuberculosis and individuals with non- tuberculosis diseases. Eur Respir J Suppl. 2013;42(57):1995.
Slogotskaya L.V., Bogorodskaya E., Sentchichina O., et al. Effectiveness of tuberculosis detection using a skin test with allergen recombinant (CFP-10-ESAT-6) in children. Eur Respir J. 2015;46(Suppl. 59):РА452.
Кудлай Д.А. Биомаркеры и иммунологические тесты. Экспериментально-клинические параллели латентной туберкулезной инфекции. Туберкулез и болезни легких. 2020;98(8):63–74. [Kudlay D.A. Biomarkers and immunological tests. Experimental and clinical parallels of latent tuberculosis infection. Tuberculosis and lung diseases. 2020;98(8):63–74. (In Russ.)].doi: 10.21292/2075-1230- 2020-988-63-74.
Аксенова В.А., Клевно Н.И., Барышникова Л.А. и др. Методические рекомендации: «Выявление туберкулеза и тактика диспансерного наблюдения за лицами из групп риска с использованием рекомбинантного туберкулезного аллергена. Диаскинтест®. М., 2011. 12 с. [Aksenova V.A., Klevno N.I., Baryshnikova L.A. et al. Methodical recommendations: “Detection of tuberculosis and tactics of dispensary observation of individuals from risk groups using a recombinant tuberculosis allergen. Diaskintest®. M., 2011. 12 p. (In Russ.)].